Targets › ATP4B
20 programs from 18 companies in 60 trials: 25 Phase 4, 20 Phase 2, 12 Phase 3, 3 Phase 1; Gastroenterology, Oncology, Genitourinary; next expected readout Nov 2026.
The beta subunit of the gastric H(+)/K(+) ATPase pump which transports H(+) ions in exchange for K(+) ions across the apical membrane of parietal cells. Plays a structural and regulatory role in the assembly and membrane targeting of a functionally active pump (By similarity). (UniProt, P51164)
Open in Phaseline: the race on ATP4B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Odense University Hospital | Capsule FMT Amiloride-sensitive sodium channel, ENaC blocker | GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1G | Phase 4 | Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women … | Dec 2026 |
| Stephen Firkins | Omeprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 4 | Marginal Ulcer | Mar 2027 |
| Prof Urs Zingg | Esomeprazol MUT Sandoz® 40mg tablet Proton pump inhibitor (PPI) | ATP4A, ATP4B | Phase 4 | Obesity | Dec 2027 |
| Dow University of Health Sciences | Dexlansoprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 4 | H. Pylori Gastrointestinal Disease | – |
| Dow University of Health Sciences | Lansoprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 4 | H. Pylori Gastrointestinal Disease | – |
| Carnot Laboratories | Tegoprazan Potassium-transporting ATPase blocker | ATP4A, ATP4B | Phase 4 | Gastroesophageal Reflux Disease; Helicobacter Pylori Infection Chronic Gastrit; Coronary Artery Disease; Ischemic Stroke … | – |
| Phathom Pharmaceuticals | Vonoprazan Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 3 | Symptomatic Non-erosive Gastroesophageal Reflux Disease; Eosinophilic Esophagitis; Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer; HELICOBACTER PYLORI INFECTIONS … | Dec 2026 |
| Il-Yang Pharm. | Ilaprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 3 | Peptic Ulcer | Aug 2027 |
| Ottawa Hospital Research Institute | Omeprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 3 | Venous Thromboembolism | Dec 2027 |
| Sherief Abd-Elsalam | Pantoprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 3 | Oncology | Dec 2030 |
| National Cancer Center, Korea | Lansoprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 3 | Gastric Cancer | Dec 2035 |
| AstraZeneca | Esomeprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 3 | Erosive Esophagitis; Liver Cirrhosis; Helicobacter Pylori Infections; Radiation Esophagitis … | – |
| Norfolk and Norwich University Hospitals NHS Foundation Trust | Lansoprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 3 | Idiopathic Pulmonary Fibrosis | – |
| The University of Texas Health Science Center, Houston | Pantoprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 2 | Acute Kidney Injury | Dec 2026 |
| United States Naval Medical Center, Portsmouth | pantoprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 2 | Postoperative Nausea and Vomiting | Dec 2026 |
| Wake Forest University Health Sciences | Omeprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 2 | Prostate Cancer | Feb 2028 |
| Universidad Autonoma de Nuevo Leon | Omeprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 2 | Morbidity | – |
| Universidad Autonoma de Nuevo Leon | Pantoprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 2 | Morbidity | – |
| Murdoch Childrens Research Institute | Omeprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 1 | Hodgkin Lymphoma | Nov 2026 |
| Caroline Samer | omeprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 1 | Healthy Volunteers | – |
HELICOBACTER PYLORI INFECTIONS (5) Helicobacter Pylori Infection (4) H. Pylori Infection (4) H. Pylori Gastrointestinal Disease (3) Acute Kidney Injury (2) Morbidity (2) Obesity (2) Oncology (2) Symptomatic Non-erosive Gastroesophageal Reflux Disease (1) Eosinophilic Esophagitis (1) Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer (1) Gastroesophageal Reflux Disease (GERD) (1)
small molecule (18), protein or peptide (1)
Universidad Autonoma de Nuevo Leon (2) Dow University of Health Sciences (2) Phathom Pharmaceuticals (1) Il-Yang Pharm. (1) The University of Texas Health Science Center, Houston (1) Ottawa Hospital Research Institute (1) Murdoch Childrens Research Institute (1) Prof Urs Zingg (1) Sherief Abd-Elsalam (1) Wake Forest University Health Sciences (1) Stephen Firkins (1) Odense University Hospital (1) Norfolk and Norwich University Hospitals NHS Foundation Trust (1) Carnot Laboratories (1) National Cancer Center, Korea (1) United States Naval Medical Center, Portsmouth (1) Caroline Samer (1) AstraZeneca (1)
ATP4A (20) GLP1R (1) CTLA4 (1) FKBP1A (1) TNF (1) PDCD1 (1) SCNN1A (1) SCNN1B (1) SCNN1G (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.